Merck Seeks To Quash Ranbaxy's Subpoenas

Law360, New York (April 2, 2008, 12:00 AM EDT) -- Merck & Co. Inc. has taken its frustrations over multiple subpoenas from generic-drug maker Ranbaxy Pharmaceuticals Inc. to a judge, claiming that the requests for information on Merck's blood pressure drug Enapren amounted to an international fact-gathering expedition.

In a third-party motion filed Monday, Merck asked the U.S. District Court for the District of New Jersey to quash a recent subpoena for information that Ranbaxy claimed it needed in its ongoing patent litigation with Pfizer Inc. in that court.

Merck said that it had been bombarded...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.